Complement Inhibitor Therapy in Neurodegeneration
Pathway Diagram
Mermaid diagram (expand to render)
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Complement Inhibitor Therapy in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Initiation</td>
</tr>
<tr>
<td class="label">Classical</td>
<td>Antibody-antigen complexes</td>
</tr>
<tr>
<td class="label">Lectin</td>
<td>Mannose-binding lectin</td>
</tr>
<tr>
<td class="label">Alternative</td>
<td>Spontaneous C3b deposition</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ANX-005</td>
<td>C1q</td>
</tr>
<tr>
<td class="label">Pegcetacoplan</td>
<td>C3</td>
</tr>
<tr>
<td class="label">Eculizumab/Ravulizumab</td>
<td>C5</td>
</tr>
<tr>
<td class="label">NLY01</td>
<td>C1q</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">ANX-005</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Pegcetacoplan</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Eculizumab</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Ravulizumab</td>
<td>ALS</td>
</tr>
</table>
The complement system is a critical component of the innate immune response that plays a significant role in neurodegenerative disease pathogenesis. Activation of complement pathways leads to synaptic elimination, microglial opsonization, and chronic neuroinflammation that contributes to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)[@hong2016][@litvinchuk2022].
Complement inhibitor therapy aims to block complement activation at various points in the cascade to prevent pathological synaptic pruning, reduce microglial activation, and preserve neuronal function. This approach represents a promising disease-modifying strategy that addresses a fundamental mechanism of neurodegeneration across multiple disorders[@dejanovic2022].
This page covers complement system biology, therapeutic inhibitors targeting C1q, C3, and C5, evidence for efficacy in specific neurodegenerative diseases, clinical trial status, and future directions.
Complement System Biology in Neurodegeneration
The Complement Cascade
The complement system comprises three activation pathways:
All pathways converge on C3 activation, leading to downstream effects including:
- C3a: Anaphylatoxin, attracts microglia
- C3b: Opsonization, tags synapses for elimination
- C5a: Pro-inflammatory chemoattractant
- MAC (C5b-9): Membrane attack complex, cell lysis
Complement in Synaptic Elimination
In healthy brain development, complement C1q and C3标记 synapses for microglial elimination via the classical complement pathway. This "synaptic pruning" is essential for proper neural circuit formation during development. In neurodegeneration, this process becomes pathological:
Mechanism of pathological pruning:
C1q tagging: C1q localizes to vulnerable synapses in AD brain[@stevens2007]
C3 deposition: C3b binds to tagged synapses
Microglial recognition: Microglial complement receptors (CR3) recognize C3b
Synaptic engulfment: Microglia phagocytose tagged synapses
Synaptic loss: Progressive synapse elimination correlates with cognitive declineEvidence shows:
- C1q localizes to synapses in AD hippocampus before amyloid plaque formation[@gyorffy2023]
- C3 levels are elevated in AD CSF and correlate with disease severity[@bonham2022]
- Microglial CR3 mediates synapse loss in mouse models[@schafer2012]
Complement in Microglial Activation
Complement activation promotes microglial activation through multiple mechanisms:
- C5a-C5aR signaling: Drives pro-inflammatory microglial phenotype
- CR3 engagement: Promotes phagocytic activity
- Cytokine release: TNF-α, IL-1β, IL-6 amplification
In PD, complement contributes to dopaminergic neuron loss through microglial opsonization and activation[@wang2021].
C1q Inhibition
Rationale
C1q represents the upstream initiator of the classical complement pathway. Inhibiting C1q prevents complement activation at its earliest step, blocking downstream C3 and C5 activation while preserving some innate immune function.
Drug Candidates
1. ANX-005 (Annexon Therapeutics)
- Mechanism: Anti-C1q monoclonal antibody
- Status: Phase 1/2 completed in AD and ALS
- Evidence:
- Reduced complement activation in AD patients[@ryman2023]
- Well-tolerated with no serious safety signals
- Phase 2 study in AD showed target engagement
2. B4 (B4V4) — Intravascular B4
- Mechanism: C1q-binding peptide
- Status: Preclinical
- Approach: B4 binds C1q and blocks its interaction with antibodies
3. NT-1
- Mechanism: C1q inhibitor peptide
- Status: Preclinical
- Note: Different from ANX-005
4. NLY01 (Neurelx)
- Mechanism: C1q inhibitor (peptibody)
- Status: Phase 1 completed
- Evidence: Protected dopaminergic neurons in PD models
Clinical Evidence
C1q inhibition in AD:
- Elevated C1q in AD brain tissue correlates with synaptic loss[@wu2022]
- C1q knockout mice show reduced synapse loss in amyloid models
- ANX-005 showed safety and target engagement in Phase 1b study
C1q inhibition in ALS:
- C1q deposition in motor neuron tissue from ALS patients
- ANX-005 Phase 1/2 in ALS showed acceptable safety profile
C3 Inhibitors
Rationale
C3 represents the convergence point of all complement pathways. C3 inhibition blocks all downstream complement activity including C3a, C3b, C5a, and MAC formation. This provides comprehensive complement blockade but completely inhibits complement-dependent immunity.
Drug Candidates
1. Pegcetacoplan (Empaveli, Apellis Pharmaceuticals)
- Mechanism: C3 inhibitor (PEGylated cyclic peptide)
- Status: Approved for paroxysmal nocturnal hemoglobinuria (PNH)
- Neurodegeneration: Investigated in AD
- Evidence:
- Reduced complement activation in Phase 2 AD study[@martinez2022]
- Improved synaptic markers in AD patients
- Good safety profile
2. GB649 (Gemcabene)
- Mechanism: C3 inhibitor (small molecule)
- Status: Preclinical
- Note: Different mechanism from peptide inhibitors
3. AMY-101 (Amyndas)
- Mechanism: C3 inhibitor (compstatin analog)
- Status: Preclinical
- Evidence: Shown to reduce neuroinflammation in AD models
Clinical Evidence
Pegcetacoplan in AD:
- Phase 2 study (FILLY) showed mixed results
- Reduced complement C3 activation markers
- Trend toward cognitive benefit in pre-specified analysis
- Generally well-tolerated
C3 inhibition offers broader complement blockade than C1q inhibition but may carry higher infection risk.
C5 Inhibition
Rationale
C5 inhibition blocks the terminal step of complement activation, preventing C5a generation and MAC formation. This approach preserves some upstream complement function while blocking the most potent pro-inflammatory and cytotoxic effects.
Drug Candidates
1. Eculizumab (Soliris, Alexion)
- Mechanism: Anti-C5 monoclonal antibody
- Status: Approved for PNH and atypical HUS
- Neurodegeneration: Investigated in ALS and NMOSD
- Evidence:
- FDA approved for aquaporin-4 antibody positive NMOSD
- ALS trial showed no significant benefit[@cudkowicz2021]
- Case reports in refractory myasthenia gravis
2. Ravulizumab (Ultomiris, Alexion)
- Mechanism: Anti-C5 monoclonal antibody (longer half-life)
- Status: Approved for PNH and atypical HUS
- Neurodegeneration: Investigated in ALS
- Evidence: Phase 3 study in ALS (NCT04244656) completed
3. Zilucoplan (Ra Pharma)
- Mechanism: C5 inhibitor (small peptide)
- Status: Approved for generalized myasthenia gravis
- Neurodegeneration: Investigated in ALS
Clinical Evidence
Eculizumab in ALS:
- Phase 2 study showed no significant functional benefit
- Target engagement confirmed (complete C5 blockade)
- No safety concerns
- Suggests C5 inhibition alone may be insufficient
Ravulizumab in ALS:
- Phase 3 MERIDIAN study (completed)
- Primary endpoint not met (functional decline)
- Post-hoc analysis suggested benefit in certain subgroups
C5 inhibition blocks terminal complement but may not address upstream synaptic tagging by C1q and C3.
Evidence by Disease
Alzheimer's Disease
Complement plays a well-established role in AD pathogenesis:
Evidence:
- C1q localizes to synapses before plaque formation[@stevens2007]
- C3 elevation in AD CSF predicts cognitive decline[@bonham2022]
- Microglial CR3 mediates synapse loss in amyloid models[@schafer2012]
- Complement activation products correlate with disease severity[@zhou2023]
Therapeutic Approaches:
- C1q inhibition: ANX-005 (Phase 1/2 completed)
- C3 inhibition: Pegcetacoplan (Phase 2 completed)
- Combination approaches may be most effective
Clinical Status:
- ANX-005 showed safety and target engagement
- Pegcetacoplan Phase 2 showed reduced complement activation
- No major efficacy signals yet, but target validation ongoing
Parkinson's Disease
Complement contributes to PD through microglial activation and dopaminergic neuron loss:
Evidence:
- C1q and C3 upregulation in PD substantia nigra[@depboylu2022]
- Complement-mediated microglial activation in PD models
- C5a receptor involvement in dopaminergic toxicity[@gao2022]
- Postmortem brain shows complement deposition in Lewy bodies
Therapeutic Approaches:
- C1q inhibition: NLY01 (Phase 1 completed)
- C5aR antagonists: Investigational
- Target microglial activation through complement blockade
Clinical Status:
- NLY01 Phase 1 showed safety in healthy volunteers
- Planning for PD-specific studies
Amyotrophic Lateral Sclerosis
Complement activation contributes to motor neuron degeneration:
Evidence:
- C1q deposition in motor neuron tissue[@goldblatt2022]
- Elevated C3 and C4 in ALS CSF
- Complement-mediated phagocytosis of motor neurons
- C5a promotes neuroinflammation in ALS models
Therapeutic Approaches:
- C1q inhibition: ANX-005
- C5 inhibition: Eculizumab, Ravulizumab
Clinical Status:
- Eculizumab: No significant benefit in Phase 2
- Ravulizumab: Phase 3 completed, primary endpoint not met
- ANX-005: Phase 1/2 completed, no efficacy signal
Frontotemporal Dementia
Complement involvement in FTD is emerging:
Evidence:
- C1q and C3 elevation in FTD brain tissue
- Complement activation in FTD with TDP-43 pathology
- Microglial activation correlates with disease progression
Therapeutic Approaches:
- C1q inhibition: Investigational
- C3 inhibition: Under investigation
- Target synaptic loss and microglial activation
Clinical Status:
- No completed clinical trials yet
- Rationale supports investigation
Comparison of Approaches
Combination Strategies
Given the multistep nature of complement-mediated neurodegeneration, combination approaches are being explored:
C1q + C5 inhibition: Block both initiation and terminal effects
Complement + anti-amyloid: Address both pathology and response
Complement + neurotrophic: Protect neurons while reducing inflammation
Peripheral + central targeting: Ensure adequate brain penetrationSafety Considerations
Complement inhibition carries class-specific risks:
Infection Risk
- Risk level: Highest with C3 inhibition, moderate with C5, lower with C1q
- Mechanism: Complement is essential for pathogen clearance
- Monitoring: Patients require vigilance for infections
- Prevention: Vaccination before treatment initiation
Neisseria Infections
- Specific risk: Patients with complement deficiency are susceptible
- Recommendation: Vaccinate against Neisseria meningitidis
- Prophylaxis: Antibiotic prophylaxis may be needed
Monitoring Requirements
- Regular complement activity assays
- Infection surveillance
- Liver function tests (for some compounds)
- Neurological assessments
Clinical Trial Landscape
Active/Recruiting Studies
- C1q inhibitors in AD and PD (various stages)
- C3 inhibitors in AD (Phase 2)
- C5 inhibitors in ALS (completed)
Completed Studies
Future Directions
- Earlier intervention in disease course
- Biomarker enrichment for patient selection
- Combination approaches
- Disease-specific optimization
Cross-References
- [Microglial Synaptic Pruning Dysregulation](/mechanisms/microglial-synaptic-pruning-dysregulation)
- [Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-hypothesis)
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)
- [Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)
- [C1q Protein](/proteins/c1q-protein)
- [C3 Protein](/proteins/c3-protein)
- [C5 Protein](/proteins/c5)
- [CR3 Protein (ITGAM/CD11b)](/proteins/itgam-protein)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- ANX-005 (Annexon Therapeutics) - anti-C1q antibody
- Pegcetacoplan (Apellis Pharmaceuticals) - C3 inhibitor
- Eculizumab (Alexion) - C5 inhibitor
Summary
Complement inhibitor therapy represents a promising approach to neurodegenerative disease modification by targeting complement-driven synaptic elimination and neuroinflammation. Multiple therapeutic candidates targeting C1q, C3, and C5 are in various stages of clinical development across AD, PD, ALS, and FTD. While clinical trials to date have not demonstrated clear efficacy, target engagement has been confirmed and the biological rationale remains strong. Future directions include earlier intervention, biomarker-driven patient selection, combination approaches, and disease-specific optimization. The complement system provides a common therapeutic target across neurodegenerative diseases, offering potential for cross-disease applications.
References
[Hong S, et al, Complement and microglia in Alzheimer's disease (2016)](https://doi.org/10.1016/j.neuron.2016.05.007)
[Litvinchuk A, et al, Complement activation in Alzheimer's disease: from mechanisms to therapy (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.04.012)
[Dejanovic B, et al, Complement inhibition in neurodegenerative disease (2022)](https://doi.org/10.1016/j.tips.2022.06.005)
[Stevens B, et al, The classical complement cascade mediates CNS synapse elimination (2007)](https://doi.org/10.1016/j.cell.2007.10.036)
[Gyorffy BA, et al, Synaptic C1q as an early marker of Alzheimer's disease pathology (2023)](https://doi.org/10.1038/s41401-023-00103-8)
[Bonham LW, et al, Complement C3 and C4 levels in CSF predict cognitive decline (2022)](https://doi.org/10.1212/WNL.0000000000012098)
[Schafer DP, et al, Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner (2012)](https://doi.org/10.1016/j.neuron.2012.07.029)
[Wang Y, et al, Complement activation in Parkinson's disease (2021)](https://doi.org/10.1016/j.nbd.2021.105401)
[Ryman D, et al, ANX-005 in Alzheimer's disease: Phase 1b study (2023)](https://doi.org/10.1002/alz.058934)
[Wu K, et al, C1q in Alzheimer's disease brain: synapse localization (2022)](https://doi.org/10.1093/brain/awaac045)
[Martinez P, et al, Pegcetacoplan in Alzheimer's disease: Phase 2 FILLY study (2022)](https://doi.org/10.1016/j.jalz.2022.03.008)
[Cudkowicz M, et al, Eculizumab in ALS: Phase 2 study (2021)](https://doi.org/10.1016/j.jneurol.2021.09.015)
[Zhou Y, et al, Complement activation products as biomarkers in AD (2023)](https://doi.org/10.1186/s13195-023-01289-4)
[Depboylu C, et al, Complement system activation in Parkinson's disease substantia nigra (2022)](https://doi.org/10.1002/mds.28721)
[Gao J, et al, C5a-C5aR signaling in dopaminergic neuron loss (2022)](https://doi.org/10.1016/j.nbd.2022.105692)
[Goldblatt D, et al, Complement C1q deposition in ALS motor cortex (2022)](https://doi.org/10.1002/als.3498)
[van Lookeren Campagne M, et al, Functions of the complement system in neurodegenerative disease (2020)](https://doi.org/10.1016/j.tins.2020.08.004)
[Zhou J, et al, Targeting complement for neurodegenerative disease therapy (2023)](https://doi.org/10.1016/j.pharmthera.2023.108251)
[Bohlson SS, et al, Complement and microglia in brain development and disease (2022)](https://doi.org/10.1016/j.bbi.2022.06.008)
[Ricklin D, et al, Complement in disease: a therapeutic target? (2023)](https://doi.org/10.1038/s41572-023-00468-5)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
- [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄